Zogenix Announces FDA Extension of Review Period for Fintepla in Dravet Syndrome

EMERYVILLE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news